← boothcheck All Stocks

ZTS

Zoetis Inc.

Zoetis Inc. (ZTS) has a dated report snapshot, but its current priced-in claim is temporarily suppressed because the live engine record is unavailable or has changed.

Live priced in
temporarily suppressed
Priced In
within-range

Key Takeaways

Zoetis sits near $79 after a roughly 21 percent single-day drop in May 2026, when a weak first quarter reset expectations for the animal-health leader. The 52-week range, from about $72 to $162, shows how far sentiment has fallen from the premium the stock used to carry. At the new price the market pays about 12 times company-wide operating income, low enough to discount a future where operating profit declines rather than grows. Most model families, growth-DCF, relative-multiple, and asset-bas

View Full Report →

Is ZTS overvalued? See what's priced in →

Institutional ownership

1,566 institutional managers reported holding ZTS in 13F filings for the quarter ended 2026-03-31. 124 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 16.1M shares were sold short as of the 2026-06-15 count, about 4% of shares outstanding (2.4 days of typical volume to cover).

Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.

Capital returns

ZTS has cut its share count 11.1% over the past five years, spending $8.82B on repurchases. It pays a dividend, and has paid one every year in our records (14 and counting), raised 13 years straight; the current rate is $2.03 a share annually. Cash returned over the past three years: $2.24B in dividends and $6.22B in repurchases.

Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.

Insider activity

No open-market insider buys on file at ZTS over the trailing three years. Absence is a fact about the company, not a signal. 23 officers and directors are on file.

Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.

Earnings reactions

ZTS's recent reports: the day-one move, then what the following quarter actually did.

reportday onenext quarter
2023-08-09+4.8%-6.5%
2023-11-03+7.1%+20.1%
2024-02-14-6.4%-17.5%
2024-05-03+5.4%+4.7%

Day-one is the close-to-close move around the filing. Nothing here is investment advice.

Recent filings

ZTS's latest 8-K filings: 2026-05-22 (items 5.02, 5.07); 2026-05-20 (items 7.01, 9.01); 2026-05-07 (items 2.02, 9.01); 2026-02-12 (items 2.02, 9.01); 2026-02-05 (items 7.01, 9.01).

Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.

Compare ZTS

Browse all stock reportsOpen the screener

Last analyzed: June 28, 2026

For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.